drug
(emtricitabine + rilpivirine hydrochloride + tenofovir disoproxil fumarate)
Marketedupdated 3mo agoby $GILD GILEAD SCIENCES, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 14, 2033
~6.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Jan 14, 2033formulationUS 10857102
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that